1. Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
   Sining Zhu et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
2. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
   Raji E Joseph et al, 2020, eLife CrossRef
3. Novel Tyrosine Kinase Targets in Urothelial Carcinoma
   Javier Torres-Jiménez et al, 2021, International Journal of Molecular Sciences CrossRef
4. Chronic Lymphocytic Leukemia Causing Gastric Ulcer Perforation: A Case Presentation and Literature Review
   Ariana R Tagliaferri et al, 2023, Cureus CrossRef
5. Rituximab combined with Bruton tyrosine kinase inhibitor to treat elderly diffuse large B-cell lymphoma patients: Two case reports
   Cang-Jian Zhang et al, 2023, World Journal of Clinical Cases CrossRef
6. Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations
   Caio Bezerra Machado et al, 2021, Pharmaceutics CrossRef
7. Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study
   Veronica Mattiello et al, 2023, Hematological Oncology CrossRef
8. Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
   Garth E. Ringheim et al, 2021, Frontiers in Immunology CrossRef